KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Shares Outstanding (2017 - 2025)

Historic Shares Outstanding for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $121.7 million.

  • Aquestive Therapeutics' Shares Outstanding rose 3342.9% to $121.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.7 million, marking a year-over-year increase of 3342.9%. This contributed to the annual value of $91.4 million for FY2024, which is 3338.63% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Shares Outstanding stood at $121.7 million for Q3 2025, which was up 3342.9% from $99.4 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Shares Outstanding peaked at $121.7 million during Q3 2025, and registered a low of $36.2 million during Q1 2021.
  • For the 5-year period, Aquestive Therapeutics' Shares Outstanding averaged around $68.3 million, with its median value being $61.6 million (2023).
  • In the last 5 years, Aquestive Therapeutics' Shares Outstanding surged by 791.68% in 2021 and then skyrocketed by 6179.35% in 2024.
  • Aquestive Therapeutics' Shares Outstanding (Quarter) stood at $41.2 million in 2021, then soared by 32.98% to $54.8 million in 2022, then rose by 25.0% to $68.5 million in 2023, then soared by 33.39% to $91.4 million in 2024, then surged by 33.09% to $121.7 million in 2025.
  • Its Shares Outstanding was $121.7 million in Q3 2025, compared to $99.4 million in Q2 2025 and $99.3 million in Q1 2025.